ERBB2 and breast cancer: To achieve the highest survival rate of HER2 BC patients, in particular those in advanced/metastatic stages, it is necessary to understand and correctly classify the resistance mechanisms to conventional anti-HER2 drugs as well as to develop more effective and less toxic therapeutic approaches.